Nordion Inc(USA)  

(Public, NYSE:NDZ)   Watch this stock  
Find more results for NYSE:MDZ
12.95
+0.01 (0.08%)
Jul 25 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 12.94 - 12.96
52 week 7.22 - 12.98
Open 12.95
Vol / Avg. 56,460.00/594,341.00
Mkt cap 801.73M
P/E 2.88
Div/yield     -
EPS 4.50
Shares 61.91M
Beta 0.63
Inst. own 85%
Sep 1, 2014
Q3 2014 Nordion Inc. Earnings Release (Estimated) Add to calendar
Jun 6, 2014
Extraordinary Shareholders Meeting
Jun 6, 2014
Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q2 (Apr '14) 2013
Net profit margin 8.97% 101.87%
Operating margin 13.46% 94.80%
EBITD margin - 11.34%
Return on average assets 4.35% 45.36%
Return on average equity 5.70% 72.49%
Employees 411 -
CDP Score - -

Address

447 March Rd.
OTTAWA, ON K2K 1X8
Canada
+1-613-5922790 (Phone)
+1-613-5926937 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Nordion Inc. (Nordion) is a global health science company. The Company is engaged in products and services used for the prevention, diagnosis and treatment of disease. The Company operates one business unit, Specialty Isotopes. It operates in two segments: Sterilization Technologies and Medical Isotopes. The Sterilization Technologies segment focuses on the prevention of disease through sterilization of medical products and devices in their final packaging, as well as microbial reduction in food and consumer products. The Company is a supplier of gamma sterilization consumables and equipment: specifically, Co-60 and production irradiators. Nordion is a supplier of medical isotopes in this market segment of the nuclear medicine industry. On July 13, 2013, Nordion completed the sale of its Targeted Therapies business to BTG, an international specialist healthcare company based in London, United Kingdom.

Officers and directors

Steven M. West President, Chief Executive Officer, Non-Independent Director
Age: 61
Bio & Compensation  - Reuters
G. Peter Dans Chief Financial Officer
Bio & Compensation  - Reuters
Grant Gardiner Senior Vice President, General Counsel, Corporate Secretary
Bio & Compensation  - Reuters
Christopher Ashwood Senior Vice President - Corporate Services
Bio & Compensation  - Reuters
Tamra Benjamin Vice President - Government and Public Affairs
Bio & Compensation  - Reuters
Scott McIntosh Chief Operating Officer - Specialty Isotopes
Bio & Compensation  - Reuters
William D. Anderson Non-Executive Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Jeffrey J. Brown Independent Director
Age: 52
Bio & Compensation  - Reuters
William G. Dempsey Independent Director
Age: 62
Bio & Compensation  - Reuters
Mary A. Mogford Independent Director
Age: 69
Bio & Compensation  - Reuters